Supply Chain

Commentary

Coronavirus response – Buy America push would hurt US. Here’s how

It is expected that any day now, the White House will release an executive order requiring certain drugs to be manufactured in the United States. It’s part of a wider push by both the administration and Congress to force the federal government to buy more American-made goods and reduce reliance on countries like China. ...
Commentary

Anti-Science Precautionary Principle Jeopardizes Health, Safety, And Risks Innovation

Medical innovations do not happen overnight. Whether it is gene therapies, new vaccines, or cutting-edge medical equipment, developing innovative medical products is a risky venture. It also takes time, lots of financial resources, and most importantly, human ingenuity. Developing new drugs, for instance, can take between 10 and 15 years. ...
Commentary

Buy American Mandates Will Weaken Our Response To The Coronavirus

Forcing a restructuring of the current pharmaceutical supply chain is a terrible idea. Yet, as a recent Wall Street Journal editorial exemplifies, there is growing support for this ill-considered policy. And, these proposals are not simply mere academic musings. The Trump Administration may implement an Executive Order that would turn this idea ...
Featured

NEW BRIEF: Expanding “Buy America” Rules Would Hurt U.S. Patients and Economy, Hinder Development of Coronavirus Vaccine

Expanding “Buy America” rules for prescription drugs and medical supplies would reduce patient access to drugs and further damage the economy, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “As the U.S. ...
Commentary

Private sector working to ensure it doesn’t get worse before it gets better

The federal government’s efforts to combat the ongoing coronavirus pandemic illustrate why we shouldn’t put our full trust in government to find a cure. After all, they badly botched the testing, costing valuable time in identifying new cases and limiting its spread. Fortunately, private-sector innovators are leading where government has ...
Commentary

In coronavirus battle, price controls would make it harder to develop lifesaving drugs

As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Commentary

Pending “Buy America” Executive Order Threatens Coronavirus Response

This week, as the coronavirus pandemic surges, President Trump is considering an executive order that would result in obstructing the movement of critical medical supplies and treatments. The new order aims to bring the pharmaceutical supply chain back to the United States by forcing federal agencies to “Buy America”—American medical equipment, American ...
Commentary

Just say no to California’s drug-making plan

California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Blog

Beyond the New Normal? Not.

Back in 2017, concerned over the sclerotic growth of the U.S. economy, PRI published a series of studies titled Beyond the New Normal by economist and PRI senior fellow Wayne Winegarden. Up until that point, annual real GDP growth averaged just 1.9 percent since 2001. Many economists, resigned to our ...
Drug Pricing

Wayne Winegarden Drug Pricing Study Featured in Healthcare Finance News

Drug supply chain, pricing system reforms will slash healthcare costs, says PRI By Jeff Lagasse As the Trump administration pushes for price caps and government controls to address prescription drug prices, a new issue brief released by the Center for Medical Economics and Innovation at the Pacific Research Institute contends ...
Commentary

Coronavirus response – Buy America push would hurt US. Here’s how

It is expected that any day now, the White House will release an executive order requiring certain drugs to be manufactured in the United States. It’s part of a wider push by both the administration and Congress to force the federal government to buy more American-made goods and reduce reliance on countries like China. ...
Commentary

Anti-Science Precautionary Principle Jeopardizes Health, Safety, And Risks Innovation

Medical innovations do not happen overnight. Whether it is gene therapies, new vaccines, or cutting-edge medical equipment, developing innovative medical products is a risky venture. It also takes time, lots of financial resources, and most importantly, human ingenuity. Developing new drugs, for instance, can take between 10 and 15 years. ...
Commentary

Buy American Mandates Will Weaken Our Response To The Coronavirus

Forcing a restructuring of the current pharmaceutical supply chain is a terrible idea. Yet, as a recent Wall Street Journal editorial exemplifies, there is growing support for this ill-considered policy. And, these proposals are not simply mere academic musings. The Trump Administration may implement an Executive Order that would turn this idea ...
Featured

NEW BRIEF: Expanding “Buy America” Rules Would Hurt U.S. Patients and Economy, Hinder Development of Coronavirus Vaccine

Expanding “Buy America” rules for prescription drugs and medical supplies would reduce patient access to drugs and further damage the economy, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “As the U.S. ...
Commentary

Private sector working to ensure it doesn’t get worse before it gets better

The federal government’s efforts to combat the ongoing coronavirus pandemic illustrate why we shouldn’t put our full trust in government to find a cure. After all, they badly botched the testing, costing valuable time in identifying new cases and limiting its spread. Fortunately, private-sector innovators are leading where government has ...
Commentary

In coronavirus battle, price controls would make it harder to develop lifesaving drugs

As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Commentary

Pending “Buy America” Executive Order Threatens Coronavirus Response

This week, as the coronavirus pandemic surges, President Trump is considering an executive order that would result in obstructing the movement of critical medical supplies and treatments. The new order aims to bring the pharmaceutical supply chain back to the United States by forcing federal agencies to “Buy America”—American medical equipment, American ...
Commentary

Just say no to California’s drug-making plan

California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Blog

Beyond the New Normal? Not.

Back in 2017, concerned over the sclerotic growth of the U.S. economy, PRI published a series of studies titled Beyond the New Normal by economist and PRI senior fellow Wayne Winegarden. Up until that point, annual real GDP growth averaged just 1.9 percent since 2001. Many economists, resigned to our ...
Drug Pricing

Wayne Winegarden Drug Pricing Study Featured in Healthcare Finance News

Drug supply chain, pricing system reforms will slash healthcare costs, says PRI By Jeff Lagasse As the Trump administration pushes for price caps and government controls to address prescription drug prices, a new issue brief released by the Center for Medical Economics and Innovation at the Pacific Research Institute contends ...
Scroll to Top